A quality by design approach to impurity method development for Atomoxetine hydrochloride (cas 82248-59-7) (LY139603)
-
Add time:07/15/2019 Source:sciencedirect.com
The development of an ion-pairing HPLC method and associated system suitability parameters for the analysis of Atomoxetine hydrochloride (cas 82248-59-7) (LY139603 HCl) using a quality by design approach is described. Potential method conditions were evaluated for their ability to meet design requirements and statistically designed experiments were used to optimize conditions and demonstrate method robustness for the separation of atomoxetine and impurities. The separation of two early eluting impurities, phenyl methylaminopropanol (PMAP (±)3-methylamino-1-phenylpropanol) and mandelic acid is correlated to the separation of other impurities that elute near the main sample component and the resolution of this peak pair is used as a system suitability test without the need for impurity reference standards.
We also recommend Trading Suppliers and Manufacturers of Atomoxetine hydrochloride (cas 82248-59-7). Pls Click Website Link as below: cas 82248-59-7 suppliers
Prev:Effect of substituent groups with two types on benzene ring on photoluminescence property of complexes of benzoic acid—Functionalized polystyrene with Eu(III) Ion
Next:Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice07/24/2019
- Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial07/23/2019
- Conditioned place preference studies with atomoxetine in an animal model of ADHD: Effects of previous atomoxetine treatment07/22/2019
- Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease07/20/2019
- Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study07/21/2019
- Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases07/19/2019
- Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat07/18/2019
- Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons07/17/2019
- Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder07/16/2019
-
Health and Chemical more >